ACIXF (Acarix AB) Additional Paid-In Capital: $74.24 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACIXF Acarix AB ACIXF
40 GF Score
Price $0.02
GF Value $0.02
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Acarix AB Additional Paid-In Capital?

Acarix AB ACIXF 40 Additional Paid-In Capital is $74.24 Mil as of Jun. 2026. GuruFocus rates ACIXF with a GF Score™ of 40/100 and a GF Value™ of $0.02 (Fairly Valued). The stock has 1 warning sign investors should review.


Acarix AB's quarterly additional paid-in capital increased from Dec. 2025 ($73.84 Mil) to Mar. 2026 ($74.26 Mil) but then stayed the same from Mar. 2026 ($74.26 Mil) to Jun. 2026 ($74.24 Mil).

Acarix AB's annual additional paid-in capital increased from Dec. 2023 ($57.73 Mil) to Dec. 2024 ($61.47 Mil) and increased from Dec. 2024 ($61.47 Mil) to Dec. 2025 ($73.84 Mil).

Acarix AB Additional Paid-In Capital Related Terms

Acarix AB Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Acarix AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acarix AB Additional Paid-In Capital Chart

Acarix AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.45 50.06 57.73 61.47 73.84

Acarix AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 70.72 72.05 73.84 74.26 74.24
ACIXF
40GF Score
Acarix AB ACIXF
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acarix AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $74.24 Mil mean?
Acarix AB (ACIXF) has a Additional Paid-In Capital of $74.24 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Acarix AB and its competitors.
Is Acarix AB's Additional Paid-In Capital too high?
Acarix AB's current Additional Paid-In Capital is $74.24 Mil. Overall, Acarix AB has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Additional Paid-In Capital compare to ABT and SYK?
Acarix AB's Additional Paid-In Capital of $74.24 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Medical Devices & Instruments company?
A good Additional Paid-In Capital depends on the Medical Devices & Instruments industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Acarix AB and its competitors. Acarix AB's current Additional Paid-In Capital is $74.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Fairly Valued. The stock's GF Value™ is $0.02, compared to a current price of $0.02 — trading 0.5% below its estimated fair value. The current Additional Paid-In Capital is $74.24 Mil. Acarix AB's overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Acarix AB (ACIXF), the current Additional Paid-In Capital is $74.24 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Acarix AB (ACIXF) Overvalued in 2026?

Based on GuruFocus' analysis, Acarix AB stock appears to be undervalued. The current stock price of $0.02 is trading 0.5% below its estimated GF Value™ of $0.02. GuruFocus considers Acarix AB to be Fairly Valued.

Key valuation signals for ACIXF:

  • Additional Paid-In Capital: $74.24 Mil
  • GF Value™: $0.02 vs. price of $0.02 (0.5% below fair value)
  • GF Score™: 40/100 with 1 warning sign

No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Acarix AB Business Description

Other Exchanges ACARIX:Sweden
Address Hyllie Boulevard 34, Regus Malmo, Malmo, SWE, 215 32
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
40GF Score

Get the complete analysis for ACIXF

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price
$0.02
GF Value